We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

OpiCapone Effect on Motor Fluctuations and pAiN (OCEAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04986982
Recruitment Status : Recruiting
First Posted : August 3, 2021
Last Update Posted : August 3, 2021
Information provided by (Responsible Party):
Bial - Portela C S.A.

Brief Summary:
The aim of this study is to investigate the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with end-of-dose motor fluctuations and associated pain

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: Opicapone 50 mg Other: Matching placebo Phase 4

Detailed Description:
This is a randomised, double-blind, placebo-controlled, multi-centre, parallel group, interventional clinical study in PD patients with end-of-dose motor fluctuations and associated pain. The study consists of a 1-week screening period, a 24-week double-blind treatment period and 2 weeks of follow-up period. The duration of treatment for the individual patient is expected to be up to 24 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 140 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomised, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Effect of Opicapone 50 mg on Parkinson's Disease Patients With End-of-dose Motor Fluctuations and Associated Pain.
Actual Study Start Date : February 25, 2021
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Opicapone

Arm Intervention/treatment
Experimental: Opicapone Drug: Opicapone 50 mg
Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI) (L-dopa/DDCI).
Other Name: BIA 9-1067

Placebo Comparator: Placebo
Opicapone and placebo capsules will be identical in size, colour, taste and appearance. The packaging and labelling will not allow for any distinction between test and reference drug.
Other: Matching placebo
Matching placebo hard capsules. Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI

Primary Outcome Measures :
  1. Change from baseline in Domain 3 (fluctuation-related pain) of King's Parkinson's Disease Pain Scale (KPPS) [ Time Frame: Up to 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Able to comprehend and willing to sign an informed consent form and to comply with all aspects of the study.
  2. Male or female patients aged 30 years or older.
  3. Experiencing PD associated pain for at least 4 weeks prior to V1.
  4. Diagnosed with idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (2006) or according to MDS Clinical Diagnostic Criteria (2015).
  5. Disease severity Stages I-III (modified Hoehn & Yahr staging) at ON.
  6. Treated with 3 to 8 intakes per day of L-dopa/DDCI (which may include a slow-release formulation), on a stable regimen for at least 4 weeks before V1.
  7. In case of any other anti-PD-treatment, it should be on a stable regimen for at least 4 weeks before V1, and not likely to need any adjustment until V6.
  8. No changes in chronic treatment regimen for pain within the last 4 weeks before V1. This includes medication (including but not limited to paracetamol, opioids, nonsteroidal anti-inflammatory drugs [NSAIDS], antidepressants, anticonvulsants and corticosteroids) and non-medication therapies (including but not limited to transcutaneous electrical nerve stimulation and bioelectrical therapy).
  9. Signs of "wearing-off" phenomenon (end-of-dose motor fluctuations) with average total daily OFF time while awake of at least 1.5 hours, excluding the early morning pre-first dose OFF, despite optimal anti-PD therapy (based on investigator's assessment).
  10. Domain 3 of KPPS ≥ 12.
  11. For females: Postmenopausal for at least 2 years before V1, surgically sterile for at least 6 months before V1, or practicing effective contraception until V6. Female patients who request to continue with oral contraceptives must be willing to use non-hormonal methods of contraception in addition during the course of this study.

    For males: Male patients who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception during the treatment period until V6.

  12. Have filled-in self-rating diary in accordance with the diary instructions and with ≤ 3 missing entries per day, in the 3 days preceding V2a/V2b.
  13. With at least 1.5 OFF hours per day, excluding the early morning pre-first dose OFF period (i.e. the time between wake-up and response to the first L dopa/DDCI dosage), as recorded in at least 2 of the 3 days in the self-rating diary for the 3 days preceding V2a/V2b.
  14. Results of the screening laboratory tests are considered acceptable by the investigator (i.e. not clinically relevant for the well-being of the patient or for the purpose of the study).
  15. Domain 3 of KPPS ≥ 12.
  16. Adequate compliance to relevant (PD and pain related) concomitant medication during the screening period (based on the investigator's judgment).

Exclusion Criteria:

  1. Non-idiopathic PD (atypical parkinsonism, secondary [acquired or symptomatic] parkinsonism, Parkinson-plus syndrome).
  2. Severe and/or unpredictable OFF periods, according to investigator judgement.
  3. Major/prominent non-PD-related pain (e.g. due to malignant disease).
  4. Treatment with prohibited medication: entacapone, tolcapone, monoamine oxidase (MAO) inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation, rasagiline up to 1 mg/day or safinamide up to 100 mg/day), or antiemetics with antidopaminergic action (except domperidone) within the last 4 weeks before V1.
  5. Previous or planned (during the entire study duration) L-dopa/carbidopa intestinal gel infusion, deep brain stimulation or stereotactic surgery (e.g. pallidotomy, thalamotomy).
  6. Treatment with apomorphine within the last 4 weeks before V1 or likely to be needed at any time until V6.
  7. Previous or current use of opicapone.
  8. Use of any other IP, currently or within the 3 months (or within 5 half-lives of the IP, whichever is longer) before V1.
  9. Past (within the past year) or present history of suicidal ideation or suicide attempts.
  10. Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine.
  11. Phaeochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
  12. Known hypersensitivity to the excipients of IP (including lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption) or of rescue medication.
  13. History of neuroleptic malignant syndrome or non-traumatic rhabdomyolysis.
  14. History of severe hepatic impairment (Child-Pugh Class C).
  15. Previous history of psychosis or psychiatric disorders, including severe major depression.
  16. Any medical condition that might place the patient at increased risk or interfere with assessments.
  17. For females: Pregnant or breastfeeding.
  18. Employees of the investigator, study centre, sponsor, clinical research organisation and study consultants, when employees are directly involved in this study or other studies under the direction of this investigator or study centre, and their family members.
  19. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04986982

Layout table for location contacts
Contact: André Garrido, BA, MA, MFA 229866100 andre.garrido@bial.com

Layout table for location information
United Kingdom
The Maurice Wohl Clinical Neuroscience Institute - King's College Hospital Recruiting
London, United Kingdom, SE5 9RT
Contact: Principal Investigator    +44 20 3299 9000      
Sponsors and Collaborators
Bial - Portela C S.A.
Additional Information:
Layout table for additonal information
Responsible Party: Bial - Portela C S.A.
ClinicalTrials.gov Identifier: NCT04986982    
Other Study ID Numbers: BIA-91067-404
2020-001175-32 ( EudraCT Number )
First Posted: August 3, 2021    Key Record Dates
Last Update Posted: August 3, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Catechol O-Methyltransferase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiparkinson Agents
Anti-Dyskinesia Agents